Therapeutic advances: Protease inhibitors for the treatment of HIV-1 infection

Journal of Clinical Pharmacy and Therapeutics

Volumn 22, Issue 2, 1997, Pages 109-117

  Misson, J ^a   Clark, W ^a   Kendall, M J ^b  

^a KEELE UNIVERSITY   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIDANOSINE; INDINAVIR; LAMIVUDINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ASTHENIA; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INFORMATION; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; ORAL DRUG ADMINISTRATION; REVIEW;

EID: 0030881580     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2710.1997.tb00004.x     Document Type: Review

References (32)

1. Fischl MA, Richman DD, Grieco MH, et al. (1987) The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. New England Journal of Medicine, 371, 185-191.
2. Fischl MA, Richman DD, Causey DM, et al. (1989) Prolonged zidovudine therapy in patients with AIDS and advanced AIDS-related complex. Journal of the American Medical Association, 262, 2405-2410.
3. 3. The AIDS Clinical Group of the National Institute of Allergy and Infectious Diseases. New England Journal of Medicine, 322(14), 941-949.
4. Concorde Co-ordinating Committee. (1994) Concorde: MRC/ANRS randomised, double-blind controlled trial in immediate and deferred zidovudine in symptom-free HIV infection. Lancet, 343, 871-881.
5. Delta Co-ordinating Committee. (1996) Delta: a randomised, double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet, 348, 283-291.
6. 3. New England Journal of Medicine, 335, 1081-1090.
7. 3. New England Journal of Medicine, 335, 1099-1106.
8. Katlama C, Ingaid D, Loveday C, et al. (1996) Safety and efficacy of lamivudine combination therapy in anti-retroviral-naive patients. Journal of the American Medical Association, 276, 118-125.
9. Staszewski S, Loveday C, Picazo JJ, et al. (1996) Safety and efficacy of lamivudine combination therapy in zidovudine-experienced patients. Journal of the American Medical Association, 276, 111-117.
10. Carpenter CCJ, Fischl MA, Hammer SM, et al. for the International AIDS Society-USA. (1996) Antiretroviral therapy for HIV infection in 1996: Recommendations of an international panel. Journal of the American Medical Association, 276, 146-154.
11. Moyle G, Gazzard B. (1996) Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs, 51(5), 701-712.
12. Donner SA, Carr A, Leonard JM, et al. (1995) A short-term study of the safety, pharmacokinetics and efficacy of ritonavir on inhibition of HIV-1 protease. New England Journal of Medicine, 333, 1528-1533.
13. Markowitz M, Saag M, Powderley WG, Hurley AM, Hsu A. (1995) A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New England Journal of Medicine, 333, 1534-1539.
14. Anon. (1996) Norvir information pack. Abbott Laboratories Ltd, Maidenhead, U.K.
15. Cameron B, Heath-Chiozzi M, Uravcik S, et al. (1996) Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir. 3rd Conference on Retroviruses and Opportunistic Infections, Washington, Abstract No. LB69.
16. Lea AP, Faulds D. (1996) Ritonavir. Drugs, 52, 541-546.
17. Danner SA. (1996) Ritonavir phase III studies: Overview. Emergence of a new approach in HIV disease management. XI International Conference on AIDS, Vancouver, p. 20. Abbott Laboratories Ltd, Maidenhead, U.K.
18. Collier AC, Coombs RW, Schoefeld DA, et al. for the AIDS Clinical Trials Group. (1996) Treatment of human immunodeficiency virus infection with saquinavir, zidovudine and zalcitabine. New England Journal of Medicine, 334, 1011-1017.
19. Noble S, Faulds D. (1996) Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs, 52, 93-112.
20. Riley G. (1996) Advantages of using saquinavir to treat HIV infection. InPharma, 1063, 13-14.
21. Salgo MP, Beattie D, Bragman K, et al. (1996) Saquinavir (invirase, SQV) vs hivid (zalcitabine, ddC) vs combination as treatment for advanced HIV infection in patients discontinuing/unable to take retrovir (zidovudine, ZDV). XI International Conference on AIDS 1996, Vancouver. Poster.
22. Vella S. (1995) Clinical experience with saquinavir. AIDS, 9(Suppl. 2), S21-S25.
23. Roberts NA. (1995) Drug resistance patterns of saquinavir and other HIV protease inhibitors. AIDS, 9(Suppl. 2), S27-S32.
24. 3. Paper presented at the 2nd National Conference Human Retroviruses and Related Infections, Washington, DC, 29 January-2 February 1995, p. 88.
25. Steigbigel RT, Berry P, Mellors J, et al. (1996) Efficacy and safety of the HIV protease inhibitor indinavir sulfate (MK639) at escalating doses. Abstract from a paper presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC, 28 January-1 February 1996.
26. Gulick RM, Mellors J, Havlir D, et al. (1996) Potent and sustained anti-retroviral activity of indinavir in combination with zidovudine and lamivudine. Abstract from a paper presented at the XI International Conference on AIDS, Vancouver, Canada, 7-12 July 1996.
27. Massari F, Staszewski S, Berry P, et al. (1995) A double-blind, randomised trial of indinavir (MK-639) alone or with zidovudine vs zidovudine alone in zidovudine naive patients. Abstract from a paper presented at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 17-20 September 1995, Program Addendum p. 9.
28. Protocol 028. (1996) Summary of clinical studies for crixivan. Data on file. Merck Sharp & Dohme Ltd, Hoddesdon, U.K.
29. Protocol 033. (1996) Summary of clinical studies for crixivan. Data on file. Merck Sharp & Dohme Ltd, Hoddesdon, U.K.
30. Massari F, Conant M, Mellors J, et al. (1996) A phase II open-label, randomised study of the triple combination of indinavir, zidovudine and didanosine versus indinavir alone and zidovudine/didanosine in antiretroviral naive patients. Abstract from a paper presented at the 3rd Conference on Retroviruses and Opportunistic Infections, Washington, DC. 28 January-1 February 1991.
31. Roberts NA. (1995) Drug resistance patterns of saquinavir and other HIV protease inhibitors. AIDS, 9(Suppl. 2), S27-S32.
32. Pinching A. (1996) Managing HIV disease after Delta. British Medical Journal, 312, 521-522.